The latest price target for Recursion Pharmaceuticals (NASDAQ:RXRX) was reported by Morgan Stanley on May 14, 2026. The analyst firm set a price target for $5.50 expecting RXRX to rise to within 12 months (a possible 54.48% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Recursion Pharmaceuticals (NASDAQ:RXRX) was provided by Morgan Stanley, and Recursion Pharmaceuticals maintained their equal-weight rating.

The last upgrade for Recursion Pharmaceuticals Inc happened on December 17, 2025 when JP Morgan raised their price target to $11. JP Morgan previously had a neutral for Recursion Pharmaceuticals Inc.

There is no last downgrade for Recursion Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Recursion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Recursion Pharmaceuticals was filed on May 14, 2026 so you should expect the next rating to be made available sometime around May 14, 2027.

While ratings are subjective and will change, the latest Recursion Pharmaceuticals (RXRX) rating was a maintained with a price target of $5.00 to $5.50. The current price Recursion Pharmaceuticals (RXRX) is trading at is $3.56, which is out of the analyst’s predicted range.